| Description | Tiragolumab(MTIG-7192A) is a monoclonal antibody that targets T-cell immunoglobulin and the ITIM structural domain (TIGIT).Tiragolumab is often used in combination with the PD-L1 inhibitor, Atezolizumab, for the treatment of solid malignant tumors such as non-small cell lung cancer. |
| Synonyms | RO 7092284, RG6058-10, MTIG-7192A, RG6058-11, RG-6058 |
| molecular weight | N/A |
| CAS | 1918185-84-8 |
| Storage | store at low temperature | store at -20°C |
| References | 1. Houssaini MS, et al. Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting. Cancer Treat Res Commun. 2020;25:100239. 2. Ge Z, et al. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. Front Immunol. 2021 Jul 22;12:699895. |